Article citationsMore>>

Traves, P.G., Murray, B., Campigotto, F., Galien, R., Meng, A. and Di Paolo, J.A. (2021) JAK Selectivity and the Implications for Clinical Inhibition of Pharmacodynamic Cytokine Signalling by Filgotinib, Upadacitinib, Tofacitinib and Baricitinib. Annals of the Rheumatic Diseases, 80, 865-875.
https://doi.org/10.1136/annrheumdis-2020-219012

has been cited by the following article:

• TITLE: Tofacitinib Combined with Hirudoid and Jinyin Peptide for the Treatment of Livedoid Vasculopathy: A Case Report

  AUTHORS: Yi Yang, Wen Zhang, Yi Sun

  KEYWORDS: Tofacitinib, Livedoid Vasculopathy, Hirudoid, Jinyin Peptide

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.15 No.6, May 25, 2026

  ABSTRACT: A 25-year-old woman presented with a 10-year history of recurrent eruptions on both lower extremities, with exacerbation during the preceding month. Routine blood and urine tests, blood biochemistry, lipid profile, humoral immune indices, and rheumatologic screening showed no obvious abnormalities; antinuclear antibody and the ENA-17 panel were negative, and color Doppler ultrasonography of the bilateral lower-extremity arteries and deep veins was unremarkable. Histopathological examination of the skin revealed fibrinoid necrosis in the superficial dermal vessel walls and intravascular thrombus formation. Livedoid vasculopathy was diagnosed. After treatment with tofacitinib combined with topical Hirudoid and Jinyin Peptide, the lesions healed.